**Endocrine Agents Growth Hormone**

| Criteria 1 | Non-Preferred Agents- Humatrope, Nutropin, Omnitrope, Saizen, Serostim, Skytrofa, Zomacton |
| ---------- | ------------------------------------------------------------------------------------------ |
| Criteria 2 | Preferred Agents- Genotropin (PA), Norditropin (PA)                                        |

  

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Endocrine Agents: Growth Hormone</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>HUMATROPE</td>
<td>028713</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HUMATROPE</td>
<td>029176</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMATROPE</td>
<td>029177</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUTROPIN</td>
<td>065821</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NUTROPIN</td>
<td>074867</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NUTROPIN</td>
<td>074870</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OMNITROPE</td>
<td>037909</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OMNITROPE</td>
<td>044344</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OMNITROPE</td>
<td>044346</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SAIZEN</td>
<td>043027</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SAIZEN</td>
<td>44087108801 </td>
<td>NDC </td>
</tr>
<tr class="odd">
<td></td>
<td>SAIZEN</td>
<td>058287</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEROSTIM</td>
<td>018100</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEROSTIM</td>
<td>022655</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEROSTIM</td>
<td>043027</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SKYTROFA</td>
<td>082607</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SKYTROFA</td>
<td>082608</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SKYTROFA</td>
<td>082609</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SKYTROFA</td>
<td>082610</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SKYTROFA</td>
<td>082611</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SKYTROFA</td>
<td>082612</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SKYTROFA</td>
<td>082613</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SKYTROFA</td>
<td>082614</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SKYTROFA</td>
<td>082615</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ZOMACTON</td>
<td>021444</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ZOMACTON</td>
<td>043027</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>0997</td>
<td> </td>
<td>Select </td>
<td>What is the patient’s age?</td>
<td>Pediatric (under 18 years of age)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adult (18 years of age or older)</td>
<td>2000</td>
</tr>
<tr class="odd">
<td>2 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1233</td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?</td>
<td>Y</td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000</td>
<td></td>
<td>Select </td>
<td>Is the patient being treated and followed by a pediatric endocrinologist, nephrologist, clinical geneticist, endocrinologist, or gastroenterologist (as appropriate for diagnosis)?</td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation to justify criteria being met, including height, weight, bone age (children), date and results of most current x-ray, stimulus test results, IGF-1 levels and a growth chart (children)?</td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select </td>
<td>Does the provider attest that the requested drug is not being used in combination with another somatropin agent?</td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">one preferred</span> drug?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1004</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1005</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1006</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>11</td>
<td>2000</td>
<td></td>
<td>Select</td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>2001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>12</td>
<td>2001</td>
<td></td>
<td>Select </td>
<td>Is the patient being treated and followed by an endocrinologist?</td>
<td>Y</td>
<td>2002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>13</td>
<td>2002</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of growth hormone deficiency by means of a negative response to an appropriate stimulation test (clonidine test is not acceptable for adults)?</td>
<td>Y</td>
<td>2003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>14</td>
<td>2003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline evaluation of the following clinical indicators: (1) insulin-like growth factor (IGF-1); (2) fasting lipid profile; (3) BUN; (4) fasting glucose; (5) electrolyte levels; (6) evaluation of any new osteoarthritis and joint pain; (7) bone density test?</td>
<td>Y</td>
<td>2004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>15</td>
<td>2004</td>
<td></td>
<td>Select</td>
<td>Does the provider attest that other hormonal deficiencies are addressed with adequate replacement therapy?</td>
<td>Y</td>
<td>2005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>16</td>
<td>2005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">one preferred</span> drug?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>2007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>2006</td>
</tr>
<tr class="odd">
<td>17</td>
<td>2006</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use.</p></td>
<td>Y</td>
<td>2007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>18</td>
<td>2007</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>2008</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>19</td>
<td>2008</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>20</td>
<td>1233</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring (i.e., height, weight gain, improved body composition)?</td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>21</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation by an endocrinologist that discontinuing the requested agent would have a detrimental effect on body composition or other metabolic parameters?</td>
<td> Y    </td>
<td>END (Pending Manual Review)  </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>22</td>
<td>1235 </td>
<td> </td>
<td>Free Text </td>
<td>Please provide the rationale for the medication being requested.  </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>23</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial approvals- 180 days; Reauthorizations-
365 days

| **Last Approved ** | 4/13/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Endocrine Agents: Growth Hormone</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>024494</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>040471</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>043434</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>043435</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>043436</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>043437</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>043438</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>045274</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>045275</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>045276</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>GENOTROPIN</td>
<td>045277</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>GENOTROPIN</td>
<td>045278</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NORDITROPIN</td>
<td>058667</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NORDITROPIN</td>
<td>058668</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NORDITROPIN</td>
<td>058669</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NORDITROPIN</td>
<td>065287</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>0997</td>
<td> </td>
<td>Select </td>
<td>What is the patient’s age?</td>
<td>Pediatric (under 18 years of age)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adult (18 years of age or older)</td>
<td>2000</td>
</tr>
<tr class="odd">
<td>2 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1233</td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?</td>
<td>Y</td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000</td>
<td></td>
<td>Select </td>
<td>Is the patient being treated and followed by a pediatric endocrinologist, nephrologist, clinical geneticist, endocrinologist, or gastroenterologist (as appropriate for diagnosis)?</td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation to justify criteria being met, including height, weight, bone age (children), date and results of most current x-ray, stimulus test results, IGF-1 levels and a growth chart (children)?</td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select </td>
<td>Does the provider attest that the requested drug is not being used in combination with another somatropin agent?</td>
<td>Y </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>2000</td>
<td></td>
<td>Select</td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>2001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>8</td>
<td>2001</td>
<td></td>
<td>Select </td>
<td>Is the patient being treated and followed by an endocrinologist?</td>
<td>Y</td>
<td>2002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>2002</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of growth hormone deficiency by means of a negative response to an appropriate stimulation test (clonidine test is not acceptable for adults)?</td>
<td>Y</td>
<td>2003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>10</td>
<td>2003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline evaluation of the following clinical indicators: (1) insulin-like growth factor (IGF-1); (2) fasting lipid profile; (3) BUN; (4) fasting glucose; (5) electrolyte levels; (6) evaluation of any new osteoarthritis and joint pain; (7) bone density test?</td>
<td>Y</td>
<td>2004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>11</td>
<td>2004</td>
<td></td>
<td>Select</td>
<td>Does the provider attest that other hormonal deficiencies are addressed with adequate replacement therapy?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>12</td>
<td>1233</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring (i.e., height, weight gain, improved body composition)?</td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>13</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation by an endocrinologist that discontinuing the requested agent would have a detrimental effect on body composition or other metabolic parameters?</td>
<td> Y    </td>
<td>END (Pending Manual Review)  </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>14</td>
<td>1235 </td>
<td> </td>
<td>Free Text </td>
<td>Please provide the rationale for the medication being requested.  </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial approvals- 180 days; Reauthorizations-
365 days

| **Last Approved ** | 4/13/2023 |
| ------------------ | --------- |
| **Other**          |           |
